ABT
Abbott Laboratories
- Operating cash flow, 2025
- $9.6B
- YoY, 2025
- +11.8%
- 5-year CAGR
- +3.9%
- 10-year CAGR
- +12.4%
Operating cash flow
Operating cash flow by fiscal year
| Period | Operating cash flow | YoY |
|---|---|---|
| 2025 | $9.6B | +11.8% |
| 2024 | $8.6B | +17.9% |
| 2023 | $7.3B | −24.2% |
| 2022 | $9.6B | −9.0% |
| 2021 | $10.5B | +33.3% |
| 2020 | $7.9B | +28.8% |
| 2019 | $6.1B | −2.6% |
| 2018 | $6.3B | +13.1% |
| 2017 | $5.6B | +73.9% |
| 2016 | $3.2B | +8.0% |
| 2015 | $3.0B | −19.3% |
| 2014 | $3.7B | +10.6% |
| 2013 | $3.3B | −64.3% |
| 2012 | $9.3B | +3.8% |
| 2011 | $9.0B | +2.7% |
| 2010 | $8.7B | +20.1% |
| 2009 | $7.3B | +4.0% |
| 2008 | $7.0B | +34.9% |
| 2007 | $5.2B | — |